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Abstract 
Introducti n: The worldwide incidence of biliary tract carcinoma (BTC; tumours of 
the bile ducts and gall-bladder) continues to rise with the only potentially curative 
treatment remaining surgical resection or transplantation, possible in only a minority 
of patients. Late presentation and a paucity of effective treatments mandate the 
development of techniques for early lesion detection.  
Areas Covered: This article reviews currently available biomarkers for the diagnosis 
and prognosis of BTC, as well as recently published studies describing novel serum, 
bile and urinary biomarkers. 
Expert Opinion: The incorporation of novel analysis techniques, such as digital 
image analysis and fluorescence in situ hybridization, into existing management 
algorithms may enhance the accuracy of brush cytology taken at the time of 
therapeutic endoscopy. However, a key goal is the discovery of reliable non-invasive 
biomarkers with high sensitivity and specificity. Recent advances in gene sequencing 
and expression, clonal evolution and tumour heterogeneity in other cancers should 
advance understanding of BTC tumour biology and facilitate biomarker discovery. 
 
 
Keywords: Cholangiocarcinoma; Biliary Tract Cancer; Gallbladder Cancer; 
Biomarkers; Diagnosis; Prognosis
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1. Introduction 
Biliary tract carcinoma (BTC) comprises tumours of the gallbladder and bile ducts, 
the commonest of which is cholangiocarcinoma (CCa), an adenocarcinoma arising 
from the epithelium of the biliary tract and which is predominantly diagnosed in the 
7
th
 decade of life [1]. CCa affects 1-2 per 100,000 in the UK population [2, 3] 
although the UK and worldwide incidence continues to rise with associated increasing 
mortality rates [3-6].  
CCa can usually be considered to be sporadic but certain recognised predisposing 
factors have been identified, including primary sclerosing cholangitis (PSC; CCa 
occurs in up to 40% of PSC patients), prolonged or recurrent biliary infection, liver 
fluke infection (particularly in areas where Opisthorchis viverrini is endemic [7] 
cirrhosis, Caroli disease, the presence of choledochal cysts and hepatolithiasis, and 
carcinogen exposure (dioxins, nitrosamines, alcohol and thorotrast).  BTC is also 
more prevalent in diabetics and smokers [1, 4]. CCa may occur via an adenoma-
dysplasia-carcinoma sequence, although CCa tumour biology remains poorly 
understood [8, 9]. A number of mutations exist in tissue derived from CCa specimens, 
including abnormalities in known oncogenes and tumour suppressor genes; however, 
the frequency of such mutations is difficult to accurately estimate and this 
information, to date, remains clinically unusable [10-12].  
Indeterminate biliary strictures present a diagnostic challenge to the investigating 
clinician. Many pathologies share clinical and radiological findings with the 
differentiation of BTC, PSC and autoimmune cholangiopathy remaining particularly 
difficult [13-15]. Endoscopic retrograde cholangiopancreatography (ERCP) can be 
utilized following cross-sectional radiological techniques for lesions assessment and 
biopsy with sensitivity for malignancy of 9-57% [16-19].  Endoscopic ultrasound is a 
further well-established technique that can be used in conjunction with fine needle 
aspiration (FNA) for the visualization and sampling of gallbladder, hilar and 
extrahepatic lesions, as well as peri-hilar lymph nodes and vessels with a sensitivity 
for CCa of appproximately 75% [20]. Novel techniques such as peroral single 
operator cholangioscopy (e.g. Spyglass, Boston Scientific Corp, Natick, 
Massachusetts, USA) can have improved diagnostic accuracy as compared to standard 
ERCP [21]  and has a specificity and sensitivity for visually directed biopsies of 98% 
and 49%, respectively [22]. Further novel techniques, such as Methylene blue, which 
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can successfully differentiate malignant lesions [23] and narrow-band imaging (NBI), 
which enhances the vascular pattern of the mucosal surface and can effectively 
differentiate tumour margins [24, 25], have also been utilised to augment the 
visualization of mucosa during cholangioscopy but are not routinely available. 
The majority of BTCs involve the main extrahepatic bile duct in the perihilar region 
(60-70%), whereas the remainder tend to arise within the common bile duct (CBD) 
distal to the cystic duct. Only very infrequently do tumours arise in either smaller bile 
ducts within the liver parenchyma (intra-hepatic) or within the gall-bladder [26]. CCa 
cells tend to insidiously infiltrate and spread along the biliary tract, so that patients 
often have minimal clinical symptoms until late presentation, usually with cholestasis 
and evidence of locally advanced or metastatic disease on imaging [27-29]. The only 
chance for long-term survival remains radical resective surgery with negative 
pathological margins (or, in highly selected patients, liver transplantation). These 
strategies remain possible in only a minority of selected patients and result in post-
resection five year survival rates of up to 54%, depending on site and severity of 
disease [30]. Non-surgical strategies currently provide only limited success in 
prolonging survival for those with advanced disease. Five-year survival rates in 
unresectable patients remain under 10% [30, 31] with a median survival of usually 
less than 12 months following treatment with cisplatin- and gemcitabine-based 
chemotherapy regimens [32]. 
The lack of effective treatments for advanced disease mandates the development of 
techniques for early lesion detection. Whilst efforts to discover effective serum or bile 
biomarkers for early detection are ongoing, the relative rarity of the disease and the 
frequent presence of cholestasis and cholangitis which can confound bile assays, have 
so far limited discovery efforts.  
This review assesses currently available biomarkers for the assessment of BTC, as 
well as reviewing recently published studies describing novel serum, bile and urinary 
biomarkers. A literature search was undertaken utilising PubMed and Embase search 
engines and the keywords cholangiocarcinoma; biliary tract cancer/carcinoma; 
gallbladder cancer/carcinoma; biomarkers; diagnosis; and prognosis entered in 
various combinations. 
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2. Serum Biomarkers 
Serum samples are easy to obtain and patient-acceptable, and therefore remain the 
most frequently utilized method of identifying biomarkers for CCa. 
 
2.1. Established Serum Biomarkers  
 
2.1.1. Carbohydrate Antigen 19-9 (CA19-9) 
CA19-9, or sialylated Lewis (a) antigen, remains the most widely used biomarker for 
the diagnosis of CCa. Despite this, it cannot be detected in ~7% of the population who 
are Lewis (a) antigen negative (lacking the requisite fucosyltransferase for the 
production of CA19-9 [33, 34]) and is elevated in some other upper gastrointestinal 
malignancies (e.g. stomach and pancreatic adenocarcinoma), primary biliary cirrhosis, 
cholestasis, cholangitis and in smokers [35]. Indeed, 10% of patients under 
investigation for BTC (based upon radiological and clinical features) are found to 
have raised CA19-9 levels, but are subsequently found to have benign disease [36]. 
Serum bilirubin levels are also an independent predictor of serum CA19-9 levels: 
following intervention for cholestasis (with a subsequent drop in serum bilirubin), 
serum CA19-9 significantly decreases in tandem [36], thus limiting its specificity in 
patients presenting with cholestasis or cholangitis. However, if serum CA19-9 levels 
remain raised after intervention for cholestasis, this is strongly predictive (although 
not diagnostic) of malignant disease [37]. Depending upon the cut-off value used, 
CA19-9 has been shown to have a sensitivity range of 78-89% and a specificity range 
of 67-87% for the diagnosis of BTC [30, 36, 38, 39]. The use of higher serum CA19-9 
cut-off levels decreases sensitivity, only allowing diagnosis of CCa to be made at an 
advanced stage of disease [33]. Further studies have attempted to use serum CA19-9 
evaluation to differentiate between PSC-related and CCa-related strictures, and 
demonstrate wide-ranging but generally low sensitivity and specificity [31, 33, 40]. 
Further, the absolute value of CA19-9 may be affected by the specific assay used, 
with one study showing that different commercial assays deliver different results, 
potentially affecting the ability of CA19-9 to discriminate between malignant and 
benign disease [41]. One method for improving the diagnostic accuracy of CA19-9 
may be to combine it with other biomarkers, such as bile-derived galectin-3-binding 
protein (LGALS3BP)/mac-2-binding protein levels, leading to significantly improved 
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diagnostic accuracy over CA19-9 alone (area under ROC curve 0.75; p<0.001) [42]. 
The sensitivity and specificity of CA19-9 also improves when combined with 
radiological imaging or endoscopic evaluation, particularly CT (computed 
tomography), MRI (magnetic resonance imaging), MRCP (magnetic resonance 
cholangiopancreatography) or ERCP (endoscopic retrograde 
cholangiopancreatography) [33]. At present, a combination of CA19-9 and 
MRI/MRCP or ultrasound represents the most effective, cost-efficient and acceptable 
technique for screening and follow-up of BTC.  
 
2.1.2. Carcinoembryonic Antigen (CEA) 
CEA is a glycosyl phosphatidyl inositol (GPI)-cell surface anchored glycoprotein that 
may be involved in cell adhesion. It is produced during foetal development, but its 
production tends to cease before birth and therefore levels in adults are generally low 
or non-existent, although they can be raised in smokers. It remains a useful biomarker 
in colorectal cancer, but is only raised in approximately 30% of patients with BTC 
[39, 43, 44]. On its own it has a limited role as a biomarker for BTC, but its clinical 
usefulness improves when used in combination with other markers [33]. 
 
2.1.3. Carbohydrate Antigen 125 (CA125) 
CA125 is a protein encoded by the MUC16 gene and is a large membrane-associated 
glycoprotein with a single transmembrane domain. It is commonly employed for the 
detection of ovarian cancer, where it has a well-established role as a biomarker, but it 
is less useful for the detection of CCa where it is only elevated in 40–50% of CCa 
patients. When elevated, it may also indicate the presence of peritoneal involvement 
[6]. 
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2.2. Novel Serum Biomarkers 
Identification of novel serum markers to supplement or replace currently utilised 
biomarkers remains crucial. However, studies to date have not been able to 
demonstrate a suitable biomarker with high diagnostic accuracy. Some of the 
currently reported serum biomarkers for BTC are summarised below (see Table 1). 
 
2.2.1. Interleukin-6 (IL-6) 
IL-6 is a major inflammatory cytokine, whose high serum levels have been shown to 
correlate well with CCa tumour burden, both pre- and post-surgical resection [45]. 
However, high values can also be found in patients with associated inflammatory 
processes, such as cholestasis and cholangitis, as well as in hepatocellular carcinoma 
(HCC), metastatic liver lesions, and some benign liver pathologies [35]. Combining 
its use with CA19-9 (or other biomarkers) may improve its diagnostic accuracy. One 
group of authors demonstrated that at a cut-off level of 25.8 pg/mL, IL-6 had a 
diagnostic sensitivity and specificity of 73% and 92% respectively (PPV and NPV 
83% and 87%, respectively), when utilized to differentiate between 26 CCa, 26 HCC 
and 23 healthy patients [46]. Serum levels were shown to correlate closely with 
tumour burden and also to decrease after treatment with photodynamic therapy. 
Similarly, the sensitivity and specificity for serum IL-6 (cut-off value 0.18 ng/mL) in 
45 CCa patients was 71% and 90% for the differentiation of CCa and benign liver 
disease (n=10), whereas the specificity for differentiating from 25 other hepatic 
tumours (15 HCC, 15 metastatic liver cancer) was only 26.7% [47]. A combination of 
leucine-rich alpha-2 glycoprotein 1 (LRG-1), CA19-9 and IL-6 was also shown to be 
capable of discriminating CCa from benign biliary pathology with high diagnostic 
accuracy [48].  
 
2.2.2. Mucins 
Mucins are cell-specific, high molecular weight, heavily O-glycosylated 
glycoproteins expressed by ductal and glandular epithelia. They can be found in either 
transmembrane or secreted forms and have roles in epithelial protection, cellular 
adhesion and signal transduction. CCa neoplasms are commonly mucin-producing 
adenocarcinomas in which abnormal expression of various mucins, including mucin1 
(MUC1) and mucin5AC (MUC5AC), has been demonstrated and linked to poor 
outcomes. Importantly, MUC5AC expression has been confirmed in serum from CCa 
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patients utilising various techniques including agarose gel electrophoresis, ELISA 
(enzyme-linked immunosorbent assay) and immunoblotting, but was not found in 
tissue derived from hepatocellular carcinomas (HCC). MUC5AC had a sensitivity and 
specificity of 71% and 90%, respectively, (area under ROC curve 0.841) for the 
diagnosis of CCa (as compared to gastrointestinal cancer patients, benign hepatic 
pathology and healthy controls) and may therefore be able to differentiate between 
tumour types [49, 50]. Further, those CCa patients with higher MUC5AC levels were 
shown to have poorer outcome (median survival 158 vs. 297 days). 
A further study investigated serum MUC5AC and bile MUC4 using real-time PCR 
and western blotting in 72 patients with biliary obstruction (39 CCa, 7 PSC) [51]. 
Serum MUC5AC was again raised in 44% of CCa patients (but not in patients with 
other malignancies), whilst bile MUC4 (collected at ERCP) was present in 27% of 
CCa cases, but not in the other malignancies. Further, those patients with either raised 
serum MUC5AC or bile MUC4 had significantly worse prognosis (median survival 
6.8 vs. 17.6 months). 
Serum MUC5AC was similarly measured in 179 CCa patients, where it was 
significantly associated with blood group A, tumours over 5cm in size and advanced 
disease, as well as poorer prognosis, as compared with patients not expressing serum 
MUC5AC (median survival, 127 vs. 329 days; P < 0.001) [52]. Those patients 
expressing serum MUC5AC also had a 2.5 times increased risk of death (p<0.001). 
In further support for the potential role of mucins in CCa biology, MUC1 positivity 
was present in 65.8% of tumours obtained from 34 patients with intrahepatic CCa, 51 
with extrahepatic CCa, 11 with gallbladder cancer and 14 patients with pancreatic 
adenocarcinoma, where it was associated with poor differentiation (p=0.002), T status 
(p=0.003) and poor patient survival (p=0.015) [53]. In the same study, MUC5AC was 
associated with advanced tumours (p=0.013) and MUC6 with well-differentiated CCa 
(p=0.006).  
 
2.2.3. CYFRA21-1 
CYFRA21-1 is a soluble fragment of cytokeratin 19, the intermediate filament protein 
that forms a crucial part of the epithelial cell cytoskeleton and is therefore 
constitutively expressed in many epithelial cells. It has been shown to be elevated in 
many different tumours including cervical, oesophageal and breast, but has a 
particular biomarker role in non small-cell lung carcinoma [54, 55]. 
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Serum CYFRA21-1 levels can differentiate intrahepatic CCa from benign liver 
disease and HCC, and have prognostic value [56]. In 55 patients who had undergone 
operative intervention for intrahepatic CCa, as compared to 90 patients with benign 
liver pathology, the AUC was higher for CYFRA21-1 than CEA or CA19-9 (0.901, 
0.779 and 0.794, respectively). It had a sensitivity and specificity of 74.7% and 92.2% 
for CCa at a cut-off value of 2.7 ng/mL. Furthermore, the 3-year recurrence-free 
survival rates were significantly worse in CCa patients with high serum CYFRA21-1 
values (25.0% vs. 76.2%) and CYFRA21-1 was found to be independently associated 
with recurrence and death following surgery on multivariate analysis [56, 57]. It has 
subsequently been postulated that raised CYFRA21-1 serum levels may represent a 
high burden of circulating tumour cells and that performing local operative resections 
in the presence of raised CYFRA21-1 may therefore prove futile [56]. 
However, another study group evaluated CYFRA21-1 in 66 patients with BTC (6 
PSC-related), 39 patients with benign biliary disease and 19 patients with PSC to 
show that at a cut-off value of 1.5 ng/mL, CYFRA21-1 had a sensitivity and 
specificity of 56% and 88%, respectively, as compared to 79% and 78% for CA19-9 
(cut-off value 37 IU/mL), concluding that it was less useful than CA19-9 [58]. A 
higher cut-off value for CYFRA21-1 (3 ng/mL) improved specificity, but decreased 
sensitivity (97% and 30% respectively). Combining CYFRA21-1 and CA19-9 (cut-
off values 1.5 ng/mL and 37 IU/mL, respectively) led to a sensitivity and specificity 
of 45% and 96% and a high level of CYFRA21-1 (>3.0 ng/mL) was a strong predictor 
of reduced median survival (2 vs. 10 months; p<0.001) [58]. 
 
2.2.4. Trypsinogen  
Tumour-associated trypsinogens 1 and 2 are the precursor zymogen forms of the 
enzyme trypsin and are encoded by the same genes as pancreatic trypsinogen. A 
recent study demonstrated that serum trypsinogen-2 (PRSS2) was capable of 
differentiating between CCa and PSC in 84 patients referred for liver transplantation 
or other hepatic surgery more effectively than CA19-9, when assessed by time-
resolved immunofluorometric assay with areas under the ROC curve (AUC) of 0.804 
and 0.613, respectively [59]. Trypsinogen-2 was also more effective at differentiating 
between PSC with and without CCa (AUC 0.759) and results were unaffected by the 
presence of other inflammatory conditions (e.g. inflammatory bowel disease) or high 
serum bilirubin levels. This potentially enhances the specificity of PRSS2 for the 
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detection of CCa, which frequently presents with cholangitis and cholestasis. 
 
2.2.5. Receptor Binding Cancer Antigen 1 (RCAS1) 
RCAS1 is a membrane protein that may participate in suppression of cell proliferation 
and induction of apoptotic cell death. Raised levels of serum RCAS1 were found in 
73.9% of BTC patients (a higher percentage than CA19-9 or CEA),  with a specificity 
of 96%, and it was suggested that it may aid in monitoring recurrence [60-62]. Its 
levels were shown to reduce to within normal limits following surgical resection, 
were not affected by the presence of cholestasis and remained elevated in some 
patients where CA19-9 was normal, thereby providing a potential complementarity.  
 
2.2.6. Dickkopf-related protein 1 (DKK1) 
DKK1, a secreted protein with cysteine-rich regions involved in multiple cellular 
processes, via its inhibitory effect on the WNT signaling pathway, has been 
implicated in both metastatic spread and local invasion in several tumour types. Shi et 
al showed that DKK1 expression was raised in CCa cell lines, as well as sera and 
tissues from patients with CCa [63]. DKK 1 expression was also associated with 
elevated matrix metalloproteinase 9, VEGF-C and metastasis to hepatic hilar lymph 
nodes. Further, DKK1 was associated with poorer overall survival and time to 
recurrence on multivariate analysis, even in patients with low risk of recurrence 
(p<0.05). DKK1 down-regulation via siRNA decreased cell migration and 
invasiveness, as well as down-regulating MMP9 and VEGF-C expression. 
 
2.2.7. Other Biomarkers 
Proteomic analysis of serum samples is now readily available. Tolek et al analyzed 
serum proteomes from six CCa patients to identify 36 CCa-associated proteins, with 
α1β-Glycoprotein (A1BG) and afamin (AFM) detected at consistently different levels 
in CCa patients, as compared to ten healthy controls [64]. A1BG and AFM were 
subsequently validated for their diagnostic and prognostic potential in 64 CCa patients 
where the A1BG/AFM ratio was capable of diagnosing CCa with 84.4% sensitivity 
and 87.5% specificity. Furthermore, an elevated post-surgical ratio was associated 
with involved resection margins and poorer outcome.  
Surface enhanced laser desorption/ionization (SELDI) analysis of serum from 56 CCa 
patients, 49 patients with other hepatobiliary disease, 269 patients with other cancers 
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and 53 healthy controls demonstrated three specific peaks that were significantly 
lower in CCa samples as compared to controls [65]. The peaks were all identified as 
variants of transthyretin (TTR or prealbumin), a largely hepatically-derived 55-kDa 
protein which functions as a serum and cerebrospinal fluid carrier of thyroxine and 
thyroid hormones. TTR serum levels were subsequently assessed and confirmed to be 
decreased in CCa. Combining it with CA19-9 gave a sensitivity and specificity of 
98.2% and 100.0% respectively, for differentiating CCa from benign disease. 
However, TTR levels are also reduced in liver disease, malnutrition and acute 
inflammation, as well as other cancers such as ovarian, cervical and endometrial. 
Vascular endothelial growth factor (VEGF), a platelet-derived growth factor crucial 
for the stimulation of vasculogenesis and angiogenesis has been implicated in the 
proliferation and metastasis of a variety of solid tumours. Levels of serum VEGF 
were significantly higher in 29 patients with extrahepatic CCa and 19 patients with 
pancreatic cancer than in 25 patients with benign biliary pathologies (CBD stones, 
PSC and cholangitis) undergoing ERCP (0.97 ng/mL (p=0.0016) and 0.66 ng/mL 
(p<0.001) vs. 0.28 ng/mL, respectively) [66]. In contrast, bile concentrations of 
VEGF were similar between the three groups.  
Li et al investigated levels of serum M2-PK, the dimeric form of the pyruvate kinase 
isoenzyme M2, which is responsible for energy production within the glycolytic 
pathway by catalyzing the dephosphorylation of phosphoenolpyruvate to pyruvate. 
M2-PK is the predominant isoform found within proliferating cells, such as 
fibroblasts, embryonic cells and stem cells and has been implicated in the metabolism 
of various tumour types. In 115 patients with CCa, 85 with benign disease and 120 
healthy blood donors, both M2-PK and CA19-9 were significantly higher in those 
with CCa and M2-PK was more sensitive and specific than CA19-9 for the diagnosis 
of malignancy (84.2% vs. 68.4% and 90% vs. 75%, respectively) [67]. 
Jamnongkan et al investigated oxidized alpha-1 antitrypsin, an oxidative stress 
indicator for many pathological states, in opisthorchis-related CCa tissue and serum to 
demonstrate that patients with high tissue levels had a poorer prognosis [68]. Serum 
levels of oxidized alpha-1 antitrypsin were also significantly raised in patients with 
heavy infections, advanced periductal fibrosis and CCa, as compared to healthy 
controls (p<0.001) and raised serum levels had an OR for CCa of 22.0, potentially 
representing a promising serum marker in areas where opisthorchis infection is 
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endemic. Further, SMAD7, involved in epithelial-mesenchymal transition has been 
found to be elevated in CCa tissue and elevated expression associated with lymph 
node metastsis, perineural invasion and survival [69]. 
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3. Bile Biomarkers 
Bile provides a rich source of potential CCa biomarkers as it is more local to the 
tumour than serum. However, its collection remains an invasive process with 
significant potential complications and its use as a screening tool is therefore limited. 
The following reviews putative biomarkers identified within bile. 
 
3.1. Insulin-like Growth Factor-1 (IGF1) 
Human CCa tissues express IGF1, a 70 amino acid peptide hormone similar in 
molecular structure to insulin and which plays an important role in growth and 
anabolic processes, thereby also having a potentially crucial role in tumour 
development and proliferation [70]. IGF1 levels measured in bile from patients with 
biliary obstruction undergoing ERCP were up to 20 times higher in patients with 
extrahepatic CCa (n=29) than those with pancreatic cancer (n=19) or benign biliary 
abnormalities (bile duct stones, PSC, cholangitis; n=25) (mean, 84.6 nmol/L vs. 5.8 
nmol/L vs. 4.1 nmol/L; p<0.001 with an area under the ROC curve of 1.0) [66]. 
Serum IGF-1 levels were also measured, but were similar between the three groups. 
 
3.2. Elastase 
Gene expression analysis, 2D electrophoretic analysis and mass spectrometry of 
fasting bile samples from patients undergoing ERCP or transhepatic catheterisation 
for biliary obstruction from malignant or benign causes (CCa or ductal stones ) 
demonstrated up-regulation of elastase mRNA, protein expression, and elastase 
activity in CCa compared to gallstone patients. The specific form was found to be 
elastase 3B, a pancreas-derived 29kDa serine protease, similar to classical pancreatic 
elastase 1.  
Biliary amylase levels were utilized to correct for the presence of pancreaticobiliary 
reflux and bile elastase/amylase ratios were significantly raised in CCa patients as 
compared to gallstone patients (0.214+/-0.045 vs. 0.023+/-0.005, respectively; 
p<0.001) with an area under the ROC curve of 0.877. Moreover, the ratio had a 
sensitivity and specificity of 82% and 89% respectively, for differentiating malignant 
and benign causes of biliary obstruction (cut-off value 0.065) [71]. 
 
3.3. Mini Chromosome Maintenance (MCM) 
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MCM is the process of initiation and elongation of DNA replication and MCM 
replication proteins have been used as markers of dysplasia for the diagnosis of 
cervical and bladder cancer. Immunofluorometric analysis of bile sediment samples 
demonstrated that levels of MCM5, a protein which plays a role in transition from the 
G0 to G1/S phases of the cell cycle, were significantly more sensitive than brush 
cytology for the diagnosis of CCa (66 % vs. 20%, respectively; p=0.004) with a 
comparable positive predicted value (97% vs. 100%, respectively; p=ns) in 60 
patients with biliary strictures of indeterminate aetiology [72]. 
 
3.4. Other Biomarkers 
Relative bile fibronectin concentrations (absolute fibronectin level divided by 
concentration of bile acids) measured in 62 gallstone patients with cholangitis, 5 with 
benign strictures and 28 with CCa were significantly different between the groups; 
and with a cut-off value of 40 ng/µmol, its sensitivity and specificity for the diagnosis 
of CCa was 57% and 79%, respectively [73]. However, its increase in patients with 
cholangitis and cholestasis may limit its usefulness for the diagnosis of CCa. 
Shen et al recently compared bile protein expression profiles from patients with 
cholangitis and CCa, utilising a classic 2D gel and MS approach, identifying 97 
differentially expressed protein spots derived from 49 different genes, 38 of which 
were up-regulated in CCa bile [74]. One of these proteins, spermatogenesis-associated 
protein 20 (SPATA20), was confirmed as being significantly upregulated in bile from 
CCa patients, and had a sensitivity and specificity for CCa diagnosis of 90.0% and 
83.3% respectively. Alternate methods for bile sample preparation for proteomic 
analysis have also been employed, including prefractionation to enrich glycoproteins, 
leading to detection of CEA-related cell adhesion molecule 1, CA125, MUC2 and 
Galectin-3-binding protein (LGALS3BP), a highly glycosylated protein implicated in 
tumour development [57].  
Dhar et al measured plasma and bile M2-PK levels in 88 patients with BTC, 79 with 
benign biliary diseases, and 17 healthy controls. Sensitivity (90.3%) and specificity 
(84.3%) of bile M2-PK for malignancy were significantly higher than those for 
plasma M2-PK and serum CA19-9 [75]. 
Alpini et al demonstrated that serotonin metabolism is dysregulated in CCa and that 
increased serotonin can be found in bile from CCa patients, where it may have 
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implications for CCa cell growth [76]. The same group went on to show that mRNA 
and protein expression of the dopamine synthesis enzymes tyrosine hydroxylase and 
dopa decarboxylase were increased in CCa cell-lines and human biopsies [77]. 
Similarly, monoamine oxidase A (MAOA) was assessed in CCa and non-malignant 
controls to show that its expression correlated with differentiation, invasion and 
survival and that the MAOA promoter was hypermethylated upstream of the start 
codon in CCa samples and cell-lines. Further, IL-6 decreased MAOA expression [78] 
and may also upregulate progranulin expression and secretion via the 
ERK1/2/RSK1/C/EBPβ in CCa cell-lines and tissues where it increased CCa growth 
by an Akt-dependant mechanism [79]. 
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4. Urinary Biomarkers 
Urine also provides an easy and acceptable source for analysis of biomarkers, 
although its use in CCa remains limited to date. Metabolic profiling of small waste 
products in urine may, in the future, be able to identify certain patterns indicative of 
metabolic changes taking place in those with CCa. Proteomic analysis of urine via 
capillary electrophoresis mass spectrometry recently assessed the distribution of 42 
peptides (most being fragments of interstitial collagens of extra-renal origin) to 
correctly identify 35 of 42 CCa patients and 64 of 81 PSC and benign pathology 
patients with a sensitivity of 83% and a specificity of 79% [80]. Further, all of those 
with CCa in addition to PSC were correctly identified. 
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5. Conclusion 
Currently, the most widely utilized biomarkers for diagnosis of CCa include serum 
CA19-9, CA125 and CEA. However, CA19-9 levels are altered in a number of benign 
conditions, as well as in other upper abdominal malignant conditions. Further, 
approximately 7% of the population is Lewis negative and do not produce CA19-9, 
and it can also be low in up to 50% of patients with CCa. Similarly, CA125 and CEA 
are not consistently elevated in CCa patients and can be raised in a variety of both 
benign and malignant conditions. Thus, the need for better diagnostic and prognostic 
biomarkers in biliary tract carcinoma remains. A number of novel serum and biliary 
biomarkers have therefore been recently proposed. Models that combine multiple 
markers appear to significantly improve the diagnostic accuracy of existing markers 
such as CA19-9 and the identification of a suitable biomarker panel may provide a 
more viable means of success than any individual marker. However, further studies 
are required to replicate initial findings and investigate their applicability in a clinical 
setting. 
The difficulty of obtaining bile for population screening and the lack of effective 
(both specific and sensitive) serum biomarkers means that suitable biomarkers for 
early detection and population screening are lacking. Alternate sources of biomarkers, 
including bile-rich gastric fluid via nasogastric aspiration or capsule endoscopy may 
ultimately prove to be a better technique. Further, a better understanding of tumour 
biology and the influence of various hormones and systemic factors may be necessary 
before effective biomarkers are found. 
Possible future techniques for novel biomarker discovery include proteomic and gene 
expression profiling and the use of combinations of biomarkers to aid both diagnosis 
and choice of treatment regimen. However, proteomic analysis of bile and serum 
retains inherent problems in that they have very large dynamic ranges of expression 
with relatively few abundant proteins making up most of the protein content and 
contain contaminants that necessitate a significant degree of sample processing for 
their removal prior to analysis. 
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6. Expert Opinion  
Current biomarkers for the diagnosis of BTC have limited sensitivity and specificity, 
with particular difficulty in distinguishing PSC-related and malignant strictures, 
potentially contributing to late diagnosis with subsequent high mortality rates. The 
incorporation of novel analysis techniques, such as digital image analysis (DIA) and 
fluorescence in situ hybridization (FISH), into management algorithms may enhance 
the sensitivity of samples taken at ERCP, whilst maintaining the high specificity of 
brush cytology, which can be difficult to interpret, particularly in patients with PSC 
[81, 82]. CCa has been associated with mutations in several oncogenes and up to 80% 
of tumour cells have been shown to exhibit chromosomal aneuploidy [83]. FISH and 
DIA can therefore be used to assess for the presence of these DNA abnormalities in 
brush cytology.  They have been shown to improve the overall sensitivity for 
detecting CCa [82] and in PSC, where confirmation of CCa is particularly 
challenging, presence of polysomy is highly suggestive of CCa [84]. Similarly, 
techniques capable of assessing DNA-ploidy, such as flow cytometry, may improve 
the sensitivity of brush cytology [85]. However, such techniques require further 
validation and their routine use has only been adopted by a few centres [86]. 
Similarly, models that combine multiple biomarkers may improve the diagnostic 
accuracy of existing markers such as CA19-9 and the identification of a suitable 
biomarker panel that can be incorporated into treatment pathways may provide good 
diagnostic accuracy in the future. 
A key goal in BTC is the discovery and validation of reliable, easily and consistently 
measurable biomarkers with good sensitivity and specificity. Statistical modelling of a 
biomarker signature in pancreatic cancer suggests that targeting 85% specificity 
would be acceptable in an enriched screening population with a cancer risk of <1%, 
results which may be applicable to specific at-risk groups in BTC (e.g. PSC) [87]. A 
better understanding of the  underlying tumour biology of BTC would facilitate 
biomarker development. Various molecular processes have been described as being 
initiated during chronic cholestasis and associated local inflammation, such as that 
found during PSC, including release of various pro-inflammatory factors such as IL-6 
and -8, tumour necrosis factors, tumour growth factors and platelet-derived growth 
factors into the local environment, which may ultimately lead to DNA damage, 
apoptotic escape mechanisms and initiation of pro-oncological pathways, such as p53, 
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p73, Smad4, K-ras, KIT, Bcl-2, survivin, cadherins and matrix metalloproteinase 7 
[88-90]. Ultimately, such mechanisms may drive the development of BTC. Further, in 
patients with PSC, various cell-cycle and apoptotic control mechanisms, including 
those influenced by p53, Bcl-2, Bax and COX-2 pathways all played crucial roles in 
the pathogenesis of 128 BTCs  (70 extrahepatic, 42 intrahepatic, 16 gallbladder) 
combined in a tissue microarray [91]. There was also differential expression of p16, 
p53 and Bcl-2 between intra- and extrahepatic CCa. p16 levels have subsequently 
been identified as having prognostic significance [91-94], as have the expression 
levels of epithelial-mesenchymal transition related genes, previously implicated in 
malignant invasion and poor prognosis [95] and HER3 of the receptor protein tyrosine 
kinase family [96]. Further, a specific isoform of p53 (∆133p53) has now been 
identified as being associated with shorter overall survival than alternate p53 isoforms 
[97].  
However, many of these pathways are crucial to multiple tumour types and little is 
known of the specific tumour biology underlying BTC development and progression. 
Comparison of intrahepatic CCA and HCC (n=11 and 24, respectively) tumours 
demonstrated specific chromosomal gains in CCa (20q, 5p, 7q, and 13q) as compared 
to HCC (gains in1q and loss of 4q, 10q and 13q) [98]. Similarly, in 50 BTC tumours, 
gains in 1q, 8q and 20q and losses in 5q, 8q, 9p and 18q were consistently found in 
early and advanced tumours with loss of 9p being the commonest abnormality (78% 
T1/2 and 68% T3/4) and the types of gains altered as per the presence or absence of 
lymph node (gains of 5p and 19q13 and losses of 6q14-q16) or distant metastatic 
disease (7p12-p14 (P<0.003), 7p21-pter (P<0.007) and 7q31 (P<0.01)) [99]. Andresen 
et al utilized an epigenetic technique to identify that various proteins involved in 
signaling and oncogenic pathways, including cysteine dioxygenase type 1 (CDO1), 
serine/threonine-protein kinase DCLK1, secreted frizzled-related protein 1 (SFRP1) 
and zinc finger and SCAN domain containing 18 (ZSCAN18) had high methylation 
frequencies in 93 CCa samples, as compared to being unmethylated in 43 control 
samples, with at least one of these four biomarkers being present in 87% of samples 
with a specificity of 100% [100].  
microRNAs (miRNAs) are small non-coding RNAs (approximately 22  nucleotides) 
involved in regulating the expression of multiple genes and multiple cellular 
processes (including cell cycle, proliferation, apoptosis and migration) under both 
physiological and pathological conditions. This may also hold true for the 
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development and progression of BTC [101, 102] and their expression may be 
epigenetically regulated by hormonal factors involved in tumour cell growth, such as 
IL-6 [103, 104]. Certain miRNAs, such as miR-421, miR-2 and miR-26a, are capable 
of acting in a pro-oncogenic fashion by down-regulating the effects of genes involved 
in tumour suppression such as FXR (farnesoid X receptor), arsenic resistance protein-
2, PTEN (phosphatase and tension homolog) and glycogen synthase kinase, and have 
been shown to be upregulated in CCa [105-108]. miRNA-25, which may help in 
regulating apoptotic pathways by protecting cholangiocytes from tumour necrosis 
factor and programmed cell death protein 4, is over-expressed in CCa [109, 110]. 
Other miRNAs, such as miR-320, miR-204 and miR-29b which attenutate pro-
apoptotic pathways, have been shown to be down-regulated [111, 112]. miRNA-21 
and -200b are over-expressed in CCa and may also contribute to tumour progression 
by promoting resistance to chemotherapy [113]. 
Many solid tumours, including BTC, are characterized by RNA, DNA and 
chromosomal abnormalities and the initial work on gene expression, branched clonal 
evolution and tumour heterogeneity in other tumour types mandates further 
proteomic, metabolomic and genetic analysis of BTC tumours to aid understanding of 
tumour biology and facilitate biomarker develoment [114].  
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7. Highlights Box 
 
1. Sensitivity and specificity of commonly utilized biomarkers remain inadequate for 
the diagnosis of patients with BTC, and the search for novel biomarkers remains 
crucial for the early detection of lesions. 
 
2. Combinations of multiple biomarkers may improve the diagnostic accuracy of 
existing markers such as serum CA19-9. 
 
3. Novel techniques, such as DIA and FISH, could be incorporated into existing 
management algorithms to enhance the accuracy of brush cytology. 
 
4. The difficulty and invasiveness of obtaining bile for population screening mean that 
efforts should focus on the identification of an appropriate serum biomarker, unless 
alternate ways of obtaining bile for analysis (e.g. bile-rich gastric fluid via nasogastric 
aspiration or capsule endoscopy) prove effective. 
 
5. Techniques for novel biomarker identification include proteomic and gene 
expression profiling; however, proteomic analysis of both bile and serum remains 
difficult due to the large dynamic ranges of expression with relatively few abundant 
proteins making up most of the protein content. 
 
6. Improved understanding of tumour biology may allow targeted analysis of serum 
and bile samples for effective biomarkers. 
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  No. Samples Performance  
Biomarker/Combination 
Sample 
Type BTC 
Benign/ 
Cancer 
Controls 
Healthy 
Controls Sensitivity Specificity Reference 
IL6 Serum 26 26 23 73% 92% [46] 
IL-6 Serum 45 40 10 71% 90% [47] 
IL6/LRG1/CA19-9 Serum 31 13 - AUC 0.98 [48] 
MUC5AC Serum 179 122 74 62.6% 96.9% [50] 
MUC5AC Serum 169 60 30 71% 90% [49] 
MUC5AC Serum 39 33 - 44% 96% [51] 
CYFRA21-1 Serum 55 90 - 74.7% 92.2% [56] 
CYFRA21-1 Serum 66 58 - 56% 88% [58] 
CYFRA21-1/CA19-9 Serum 66 58 - 45% 96% [58] 
PRSS2 Serum 38  46  - AUC 0.804 [59] 
RCAS1 Serum 23 72 35 73.9% 96.2% [60] 
RCAS1 Serum 31 107 - 74.4% 91.0% [61] 
A1BG/AFM ratio Serum 64 4 20 84.4% 87.5% [64] 
TTR/CA19-9 Serum 56 322 53 98.2% 100% [65] 
VEGF Serum 29 44 - AUC 0.744 [66] 
M2-PK Serum 115 85 120 84.2% 90.0% [67] 
MAC-2BP/CA19-9 Bile 26 52 0 AUC 0.75 [42] 
IGF1 Bile 29 44 - AUC 1.000 [66] 
Elastase Bile 22 28 - 82% 89% [71] 
MCM5 Bile 27 75 - 66% N/A [72] 
Fibronectin Bile 28 67 - 57% 79% [73] 
SPATA20 Bile 35 23 47 90% 83.3% [74] 
M2-PK Bile 88 79 17 90.3% 84.3% [75] 
42 Peptides Urine 42 81 - 83% 79% [80] 
 
Table 1. A summary of recent novel biomarker studies for the diagnosis and 
assessment of patients with BTC (BTC- Biliary tract cancer; AUC- Area under ROC 
curve; MAC-2BP- MAC-2 binding protein; CA19-9- Carbohydrate antigen 19-9; IL-
6- Interleukin-6; LRG1; MUC5AC- Mucin5AC; CYFRA21-1- Soluble fragment of 
cytokeratin 19; PRSS2- Trypsinogen-2; TTR- Transthyretin; RCAS1- Receptor 
binding cancer antigen 1; A1BG- α1β-Glycoprotein; AFM- Afamin; VEGF- Vascular 
endothelial growth factor; IGF1- Insulin-like Growth Factor-1; MCM5- Mini 
chromosome maintenance protein 5; SPATA20- Spermatogenesis-associated protein 
20; M2PK- M2 isotope of pyruvate kinase). 
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